nach oben

Endocrine

Erschienen in:

03.06.2023 | Meta- Analysis

Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study

verfasst von: Soheil Hassanipour, Reza Zare, Alireza Shahedi, Hamed Delam

Erschienen in: Endocrine | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Overall, thyroid cancer is the most common endocrine malignancy. This cancer is fifth most common cancer among adult women and the second most common cancer in women over 50 years old and it occurs in women 3 times more than men. The present systematic review and meta-analysis were designed with the aim of determining the 5-year survival rate of thyroid cancer in Asian countries in 2022.

Methods

The current study is a systematic review and meta-analysis of thyroid cancer survival rates in Asian countries. Researchers in the study searched for articles published in six international databases: PubMed/Medline, EMBASE, Scopus, Google Scholar, ISI (Web of Knowledge), and ProQuest until July 03, 2022. A checklist (The Newcastle-Ottawa Quality Assessment Form) has been prepared in previous studies to evaluate the quality of articles.

Results

In general, 38 articles were entered for the meta-analysis. The 5-year survival rate was 95.3%, with a 95% confidence interval of 93.5% to 96.6%. The year of study is a cause of variability in results of 5-year (Reg Coef = 0.145, P < 0.001). According to the results, an increased survival rate across the study period was observed. Human Development Index was a cause of variability in results of 5-year survival rates (Reg Coef = 12.420, P < 0.001). The results of Table 2 showed that women have 4% more 5-year survival rate than men (Hazard ratio: 1.05 CI: 95% 1.04–1.06)).

Conclusion

In general, the 5-year survival of thyroid cancer in Asian countries was higher than in European countries, but it is at a lower level than in the United States.

H. Luo, X. Xia, G.D. Kim et al. Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci. Adv. 7(31), (2021). https://doi.org/10.1126/sciadv.abf3657

M.A. Zaballos, P. Santisteban, Key signaling pathways in thyroid cancer. J. Endocrinol. 235(2), R43–R61 (2017). /11// https://doi.org/10.1530/joe-17-0266CrossRefPubMed

C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646–653 (2016). https://doi.org/10.1038/nrendo.2016.110CrossRefPubMedPubMedCentral

A. Safavi, F. Azizi, R. Jafari et al. Thyroid cancer epidemiology in iran: a time trend study. Asian Pac. J. Cancer Prev. 17(1), 407–412 (2016). https://doi.org/10.7314/apjcp.2016.17.1.407CrossRefPubMed

C. Liu, Q. Zhao, Z. Li et al. Mixed subtype thyroid cancer: a surveillance, epidemiology, and end results database analysis. Oncotarget 8(49), 86556–86565 (2017). https://doi.org/10.18632/oncotarget.21242CrossRefPubMedPubMedCentral

M. Fiore, G. Oliveri Conti, R. Caltabiano et al. Role of emerging environmental risk factors in thyroid cancer: a brief review. 16(7), 1185 (2019). https://doi.org/10.3390/ijerph16071185

Y. Liu, L. Su, H. Xiao, Review of factors related to the thyroid cancer epidemic. Int. J. Endocrinol. 2017, 5308635 (2017). https://doi.org/10.1155/2017/5308635CrossRefPubMedPubMedCentral

Y. Wang, W. Wang. Increasing incidence of thyroid cancer in Shanghai, China, 1983–2007. 27(2), NP223–NP229 (2015). https://doi.org/10.1177/1010539512436874

J.J. Figge. Epidemiology of thyroid cancer. in Thyroid Cancer: A Comprehensive Guide to Clinical Management, eds. by L. Wartofsky, D. Van Nostrand (Springer, New York, 2016), p. 9–15

10.

C.D. Seib, J.A. Sosa, Evolving understanding of the epidemiology of thyroid cancer. Endocrinol. Metab. Clin. North Am. 48(1), 23–35 (2019). https://doi.org/10.1016/j.ecl.2018.10.002CrossRefPubMed

11.

A. Matrone, F. Ferrari, F. Santini et al. Obesity as a risk factor for thyroid cancer. 27(5), 358–363 (2020). https://doi.org/10.1097/med.0000000000000556

12.

S. Vaccarella, L. Dal Maso, Challenges in investigating risk factors for thyroid cancer. Lancet Diabetes Endocrinol. 9(2), 57–59 (2021). /2//10.1016/s2213-8587(20)30426-5CrossRefPubMed

13.

S. MU, I. KD, Modern diagnostic approachкеtreatment of thyroid cancer. Int. J. Dev. Public Policy 1(4), 101–105 (2021)

14.

M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. 10(4), 264–272 (2022)

15.

H.A. Vahedian Ardakani, M. Moghimi, M. Shayestehpour et al. Survival of patients with thyroid cancer in Yazd, Iran. Asian Pac. J. Cancer Prev. 18(8), 2293–2297 (2017). https://doi.org/10.22034/apjcp.2017.18.8.2293CrossRefPubMed

16.

A. Bikas, K.D. Burman. Epidemiology of thyroid cancer. The Thyroid and its Diseases (Springer, 2019), p. 541–547

17.

K.J. Stansifer, J.F. Guynan, B.M. Wachal et al. Modifiable risk factors and thyroid cancer. Otolaryngol. Head. Neck Surg. 152(3), 432–437 (2014). https://doi.org/10.1177/0194599814564537CrossRefPubMed

18.

L. Du, Z. Zhao, R. Zheng et al. Epidemiology of thyroid cancer: incidence and mortality in China, 2015. Front. Oncol. 10, 1702 (2020). https://doi.org/10.3389/fonc.2020.01702CrossRefPubMedPubMedCentral

19.

M. Fiore, A. Cristaldi, V. Okatyeva et al. Dietary habits and thyroid cancer risk: a hospital-based case–control study in Sicily (South Italy). Food Chem. Toxicol. 146, 111778 (2020). https://doi.org/10.1016/j.fct.2020.111778. 2020/12/01/CrossRefPubMed

20.

S. Vaccarella, S. Franceschi, F. Bray et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagno sis. N. Engl. J. Med. 375(7), 614–617 (2016). https://doi.org/10.1056/NEJMp1604412CrossRefPubMed

21.

F. Khodamoradi, M. Ghoncheh, A. Mehri et al. Incidence, mortality, and risk factors of thyroid cancer in the world: a review. 5(2), 9 (2018)

22.

J.A. Sipos, E.L. Mazzaferri, Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. 22(6), 395–404 (2010). https://doi.org/10.1016/j.clon.2010.05.004CrossRef

23.

A. Zahedi, L. Bondaz, M. Rajaraman et al. Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. 30(6), 871–877 (2020)

24.

B. Farhood, B. Raei, R. Malekzadeh et al. A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries. 23(1), 7–15 (2019). https://doi.org/10.5114/wo.2019.84112

25.

S. Deshpande, A. van Asselt, F. Tomini et al. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis: NIHR Journals Library (2013)

26.

S. Hassanipour, H. Delam, M. Arab-Zozani et al. Survival rate of prostate cancer in Asian countries: a systematic review and meta-analysis. Ann. Global Health. 86(1), (2020)

27.

E. Von Elm, D.G. Altman, M. Egger et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull. World Health Organ. 85, 867–872 (2007)CrossRef

28.

H.-A. Nikbakht, S. Hassanipour, L. Shojaie et al. Survival Rate of colorectal cancer in Eastern Mediterranean region countries: a systematic review and meta-analysis. Cancer Control 27(1), 1073274820964146 (2020)CrossRefPubMedPubMedCentral

29.

K.W. Jung, Y.J. Won, H.J. Kong et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res. Treat. 45(1), 1–14 (2013). https://doi.org/10.4143/crt.2013.45.1.1CrossRefPubMedPubMedCentral

30.

K. Jung, Y. Won, H. Kong et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2011 [Article]. Cancer Res. Treat. 46(2), 109–123 (2014). https://doi.org/10.4143/crt.2014.46.2.109CrossRefPubMedPubMedCentral

31.

K.W. Jung, S. Park, H.J. Kong et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res. Treat. 43(1), 1–11 (2011). https://doi.org/10.4143/crt.2011.43.1.1CrossRefPubMedPubMedCentral

32.

K.W. Jung, S. Park, H.J. Kong et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res. Treat. 44(1), 11–24 (2012). https://doi.org/10.4143/crt.2012.44.1.11CrossRefPubMedPubMedCentral

33.

K.W. Jung, Y.J. Won, H.J. Kong et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res. Treat. 47(2), 127–141 (2015). https://doi.org/10.4143/crt.2015.060CrossRefPubMedPubMedCentral

34.

C.M. Oh, Y.J. Won, K.W. Jung et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res. Treat. 48(2), 436–450 (2016). https://doi.org/10.4143/crt.2016.089CrossRefPubMedPubMedCentral

35.

K.W. Jung, Y.J. Won, C.M. Oh et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Res. Treat. 49(2), 292–305 (2017). https://doi.org/10.4143/crt.2017.118CrossRefPubMedPubMedCentral

36.

K.W. Jung, Y.J. Won, H.J. Kong et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2016. Cancer Res. Treat. 51(2), 417–430 (2019). https://doi.org/10.4143/crt.2019.138CrossRefPubMedPubMedCentral

37.

S. Hong, Y.J. Won, Y.R. Park et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res. Treat. 52(2), 335–350 (2020). https://doi.org/10.4143/crt.2020.206CrossRefPubMedPubMedCentral

38.

S. Hong, Y.J. Won, J.J. Lee et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res. Treat. 53(2), 301–315 (2021). https://doi.org/10.4143/crt.2021.291CrossRefPubMedPubMedCentral

39.

M.J. Kang, Y.-J. Won, J.J. Lee et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 54(2), 330 (2022)

40.

K.W. Jung, Y.J. Won, H.J. Kong et al. Cancer statistics in Korea: incidence, mortality, survival,and prevalence in 2015. Cancer Res. Treat. 50(2), 303–316 (2018). https://doi.org/10.4143/crt.2018.143CrossRefPubMedPubMedCentral

41.

H.R. Shin, D.H. Lee, S.Y. Lee et al. Cancer survival in Busan, Republic of Korea, 1996-2001. IARC Sci. Publ. 162, 155–162 (2011)

42.

Z.H. Woo, Y.C. Hong, W.C. Kim et al. Cancer survival in Incheon, Republic of Korea, 1997-2001. IARC Sci. Publ. 162, 163–169 (2011)

43.

Y.O. Ahn, M.H. Shin, Cancer survival in Seoul, Republic of Korea, 1993–1997. IARC Sci. Publ. 162, 171–178 (2011)

44.

H. Zeng, R. Zheng, Y. Guo et al. Cancer survival in China, 2003-2005: a population-based study. Int. J. Cancer 136(8), 1921–1930 (2015). https://doi.org/10.1002/ijc.29227CrossRefPubMed

45.

S.C. Law, O.W. Mang, Cancer survival in Hong Kong SAR, China, 1996-2001. IARC Sci. Publ. 162, 33–41 (2011)

46.

J.G. Chen, H.Z. Chen, J. Zhu et al. Cancer survival in patients from a hospital-based cancer registry, China. J. Cancer 9(5), 851–860 (2018). https://doi.org/10.7150/jca.23039CrossRefPubMedPubMedCentral

47.

J.G. Chen, J. Zhu, Y.H. Zhang et al. Cancer survival in Qidong, China, 1992–2000. IARC Sci. Publ. 162, 43–53 (2011)

48.

Y.B. Xiang, F. Jin, Y.T. Gao, Cancer survival in Shanghai, China, 1992–1995. IARC Sci. Publ. 162, 55–68 (2011)

49.

F. Jin, Y.B. Xiang, Y.T. Gao, Cancer survival in Shanghai, People’s Republic of China. IARC Sci. Publ. 145, 37–50 (1998)

50.

H. Xishan, K. Chen, H. Min et al. Cancer survival in Tianjin, China, 1991–1999. IARC Sci. Publ. 162, 69–84 (2011)

51.

H. Zeng, W. Chen, R. Zheng et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6(5), e555–e567 (2018)CrossRefPubMed

52.

Y. Li, L. Yu, J. Na et al. Survival of cancer patients in Northeast China: analysis of sampled cancers from population-based cancer registries. Cancer Res. Treat. 49(4), 1106–1113 (2017). https://doi.org/10.4143/crt.2016.613CrossRefPubMedPubMedCentral

53.

Y. Zhou, Z.S. Xiang, J.Y. Ma et al. Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study. Neoplasma 68(4), 892–898 (2021). https://doi.org/10.4149/neo_2021_210203N168CrossRefPubMed

54.

H. Nakagawa-Senda, M. Yamaguchi, T. Matsuda et al. Cancer prevalence in Aichi, Japan for 2012: estimates based on incidence and survival data from population-based cancer registry. Asian Pac. J. cancer Prev.: APJCP 18(8), 2151–2156 (2017). https://doi.org/10.22034/apjcp.2017.18.8.2151CrossRefPubMedPubMedCentral

55.

T. Matsuda, W. Ajiki, T. Marugame et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn. J. Clin. Oncol. 41(1), 40–51 (2011). https://doi.org/10.1093/jjco/hyq167CrossRefPubMed

56.

H. Tsukuma, W. Ajiki, A. Ioka et al. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn. J. Clin. Oncol. 36(9), 602–607 (2006). https://doi.org/10.1093/jjco/hyl068CrossRefPubMed

57.

K.S. Chia, Cancer survival in Singapore, 1993–1997. IARC Sci. Publ. 162, 183–198 (2011)

58.

N. Martin, S. Srisukho, O. Kunpradist et al. Cancer survival in Chiang Mai, Thailand. IARC Sci. Publ. 145, 109–121 (1998)

59.

S. Sriamporn, R.J. Black, R. Sankaranarayanan et al. Cancer survival in Khon Kaen Province, Thailand. Int. J. Cancer 61(3), 296–300 (1995). https://doi.org/10.1002/ijc.2910610303CrossRefPubMed

60.

V. Vatanasapt, S. Sriamporn, S. Kamsa-ard et al. Cancer survival in Khon Kaen, Thailand. IARC Sci. Publ. 145, 123–134 (1998)

61.

N. Martin, S. Pongnikorn, N. Patel et al. Cancer survival in Lampang, Thailand, 1990–2000. IARC Sci. Publ. 162, 217–226 (2011)

62.

H. Sriplung, P. Prechavittayakul, Cancer survival in Songkhla, Thailand, 1990–1999. IARC Sci. Publ. 162, 227–235 (2011)

63.

P. Jayalekshmi, P. Gangadharan, P. Sebastian, Cancer survival in Karunagappally, India, 1991–1997. IARC Sci. Publ. 162, 125–132 (2011)

64.

H.A.V. Ardakani, M. Moghimi, M. Shayestehpour et al. Survival of patients with thyroid cancer in Yazd, Iran. Asian Pac. J. Cancer Prev. 18(8), 2293–2297 (2017). https://doi.org/10.22034/APJCP.2017.18.8.2293CrossRefPubMedCentral

65.

M. Khayamzadeh, M. Khayamzadeh, N. Tadayon et al. Survival of thyroid cancer and social determinants in Iran, 2001-2005. Asian Pac. J. cancer Prev.: APJCP 12(1), 95–98 (2011)PubMed

66.

M. Aseafan, E. Devol, M. AlAhwal et al. Population-based survival for cancer patients in Saudi Arabia for the years 2005–2009. Sci. Rep. 12(1), 235 (2022). https://doi.org/10.1038/s41598-021-04374-6CrossRefPubMedPubMedCentral

67.

M. Colonna, N. Bossard N., Guizard A-V et al. editors. Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival. Annales d’endocrinologie. (Elsevier, 2010)

68.

J. Kuijpens, B. Hansen, J. Hamming et al. Trends in treatment and long-term survival of thyroid cancer in Southeastern Netherlands, 1960–1992. Eur. J. Cancer 34(8), 1235–1241 (1998)CrossRefPubMed

69.

L. Davies, H.G. Welch, Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch. Otolaryngol.–Head. Neck Surg. 136(5), 440–444 (2010)CrossRefPubMed

70.

R. Scheiden, M. Keipes, C. Bock et al. Thyroid cancer in Luxembourg: a national population-based data report (1983–1999). BMC cancer 6(1), 1–11 (2006)CrossRef

71.

C. Mirian, C. Grønhøj, D.H. Jensen et al. Trends in thyroid cancer: retrospective analysis of incidence and survival in Denmark 1980–2014. Cancer Epidemiol. 55, 81–87 (2018)CrossRefPubMed

72.

L. Dal Maso, A. Tavilla, F. Pacini et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur. J. Cancer 77, 140–152 (2017)CrossRefPubMed

73.

L.A. Akslen, T. Haldorsen, S.Ø. Thoresen et al. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res. 51(4), 1234–1241 (1991)PubMed

74.

C.I. Lundgren, P. Hall, A. Ekbom et al. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int. J. Cancer 106(4), 569–573 (2003)CrossRefPubMed

75.

M. Colonna, Z. Uhry, A.V. Guizard et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol. 39(4), 511–518 (2015). https://doi.org/10.1016/j.canep.2015.04.015CrossRefPubMed

76.

R. Elisei, E. Molinaro, L. Agate et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J. Clin. Endocrinol. Metab. 95(4), 1516–1527 (2010)CrossRefPubMed

77.

E. Goodarzi, A. Moslem, H. Feizhadad et al. Epidemiology, incidence and mortality of thyroid cancer and their relationship with the human development index in the world: an ecology study in 2018. Adv. Hum. Biol. 9(2), 162 (2019)CrossRef

78.

H. Salehiniya, R. Pakzad, S. Hassanipour et al. The incidence and mortality of thyroid cancer and its relationship with HDI in the world. World Cancer Res. J. 5(2), 1–6 (2018)

79.

M. Soheylizad, S. Khazaei, E. Jenabi et al. The relationship between human development index and its components with thyroid cancer incidence and mortality: Using the decomposition approach. Int. J. Endocrinol. Metab. 16(4), (2018)

Titel: Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study
verfasst von: Soheil Hassanipour
Reza Zare
Alireza Shahedi
Hamed Delam
Publikationsdatum: 03.06.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03408-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey

Revisiting the cortisol reference ranges in humans: the role of demographics

Smoking during pregnancy and gestational diabetes mellitus: a systematic review and meta-analysis

Long-term low-dose tolvaptan efficacy and safety in SIADH

Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia

Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin